Source-grounded facts extracted from IDEXX LABORATORIES INC /DE's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
IDEXX LABORATORIES INC /DE: Amended and restated By-Laws effective upon filing of Certificate of Amendment to incorporate declassification of the Board, procedures for special meetings, and other technical changes (effective 2026-05-13).
“On May 13, 2026, pursuant to the Board’s prior approval of certain amendments to our By-Laws, the effectiveness of which were conditioned upon and subject to the filing of a Certificate of Amendment reflecting the Approved Amendments with the Secretary of State of the State of Delaware, the Corporation’s By-Laws were amended and restated effective upon the filing of the aforementioned Certificate of Amendment (the “Amended and Restated By-Laws”).”
Governance Changes
IDEXX LABORATORIES INC /DE: Approved amendments to Certificate of Incorporation to declassify the Board over three years and provide for annual election of all directors starting at 2029 annual meeting, and to allow shareholders owning at least 25% of capital stock continuously for one year to call a special meeting (effective 2026-05-13).
“A Certificate of Amendment reflecting the Approved Amendments was filed with the Secretary of State of the State of Delaware and became effective on May 13, 2026.”
Earnings Releases
IDEXX LABORATORIES INC /DE reported the quarter ended March 31, 2026 results: revenue $1,141 million, EPS $3.47. Guidance raised.
“Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company reports revenues of $1,141 million for the first quarter of 2026, an increase of 14% as reported and 11% organic, driven by Companion Animal Group ("CAG") growth of 15% as reported and 12% organic. First quarter”
Dr. Asha Collins resigned as Director at IDEXX LABORATORIES INC /DE.
“On February 13, 2025, Dr. Asha Collins resigned from the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”), effective immediately.”
Andrew Emerson was appointed as Executive Vice President, Chief Financial Officer and Treasurer at IDEXX LABORATORIES INC /DE.
“the Board appointed Andrew Emerson, currently Senior Vice President, Corporate and Companion Animal Group (“CAG”) Finance of the Company, as Executive Vice President, Chief Financial Officer and Treasurer of the Company, effective March 1, 2025.”
Brian P. McKeon departed as Executive Vice President, Chief Financial Officer and Treasurer at IDEXX LABORATORIES INC /DE.
“Brian P. McKeon, Executive Vice President, Chief Financial Officer and Treasurer of IDEXX Laboratories, Inc. (the “Company” or “IDEXX”) notified the Company that he will retire from IDEXX effective June 1, 2025.”
Jonathan W. Ayers resigned as Member of the Board of Directors at IDEXX LABORATORIES INC /DE.
“On November 8, 2024, Jonathan W. Ayers, a member of the Board of Directors (the “Board”) of IDEXX Laboratories, Inc. (the “Company”), resigned from the Board and its finance committee, effective November 8, 2024.”
Shareholder Votes
IDEXX LABORATORIES INC /DE shareholders approved Shareholder Proposal Regarding Simple Majority Vote at the 2024-05-06 meeting.
“Proposal Four: Shareholder Proposal Regarding Simple Majority Vote. For 61,364,120 Against 6,382,985 Abstain 673,000 Broker Non-Votes 5,462,716”
Shareholder Votes
IDEXX LABORATORIES INC /DE shareholders approved Advisory Vote to Approve Executive Compensation at the 2024-05-06 meeting.
“Proposal Three: Advisory Vote to Approve Executive Compensation. For 64,265,443 Against 4,412,055 Abstain 458,539 Broker Non-Votes 5,462,716”
Shareholder Votes
IDEXX LABORATORIES INC /DE shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2024-05-06 meeting.
“Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm. For 70,547,786 Against 3,857,651 Abstain 193,316 Broker Non-Votes N/A”
Shareholder Votes
IDEXX LABORATORIES INC /DE shareholders approved Election of Irene Chang Britt, Bruce L. Claflin, Asha S. Collins, PhD and Sam Samad, each as a Class I director at the 2024-05-06 meeting.
“Proposal One: Election of Directors. Nominees For Against Abstain Broker Non-Votes Irene Chang Britt 68,830,275 114,870 190,892 5,462,716 Bruce L. Claflin 64,539,198 4,403,367 193,562 5,462,716 Asha S. Collins, PhD 67,054,357 1,892,248 189,432 5,462,716 Sam Samad 65,193,479 3,748,617 193,941 5,462,716”
Earnings Releases
IDEXX LABORATORIES INC /DE reported the quarter ended March 31, 2024 results: revenue $964 million, EPS $2.81. Guidance reaffirmed.
“Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced first quarter results. First Quarter Results The Company reports revenues of $964 million for the first quarter of 2024, an increase of 7% as reported and organic, driven by Companion Animal Group ("CAG") growth of 7% as reported and organic, and Water revenue growth”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.